ALSO NOTED: Agennix OK'd to launch late-stage lung cancer trial; QLT reorganizes; Ventana still resisting Roche bid; and much m

> Houston-based Agennix has been given a green light to launch a late-stage trial of a new therapy for lung cancer that includes an ingredient found in mother's milk. Talactoferrin closely resembles human lactoferrin, which establishes a baby's immune system. Report

> QLT is laying off more than a hundred workers and selling its QLT USA division and its Vancouver HQ is it undertakes a restructuring that will leave it focused on marketing Visudyne. Report

> Roche has extended its offer for Ventana Medical Systems, but Ventana is still urging shareholders not to tender their shares. Report

> Targacept has priced an offering of 3.8 million shares at $7.07 apiece. Report

> Eisai's takeover of MGI Pharma has been approved by federal regulators. Report

> RNCOS estimates that the global vaccines market should hit $21 billion by 2010. Report

> Doctors overprescribe brand-name meds, and it's pharma's fault. Or so says a new report from the UK's Committee of Public Accounts. Report

> Did Schering-Plough execs peek at the Vytorin trial data and, spooked, bail out of millions worth of stock? Report

And Finally… In what may become the most far-reaching effects of the failed Vytorin trial, experts are questioning the sacred link between cholesterol and heart disease. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.